Equities research analysts expect Humana Inc. (NYSE:HUM) to post $3.23 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for Humana’s earnings, with estimates ranging from $3.10 to $3.32. Humana reported earnings per share of $3.18 in the same quarter last year, which would indicate a positive year-over-year growth rate of 1.6%. The firm is expected to report its next quarterly earnings results on Friday, November 3rd.

On average, analysts expect that Humana will report full year earnings of $11.54 per share for the current year, with EPS estimates ranging from $11.47 to $11.63. For the next financial year, analysts anticipate that the company will post earnings of $12.25 per share, with EPS estimates ranging from $11.95 to $12.92. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Humana.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The firm had revenue of $13.53 billion for the quarter, compared to analyst estimates of $13.61 billion. During the same quarter last year, the firm posted $2.30 earnings per share.

Several analysts have recently commented on HUM shares. Citigroup Inc. started coverage on Humana in a report on Wednesday, June 28th. They set a “buy” rating and a $275.00 target price on the stock. BidaskClub lowered Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $253.00 price target on the stock in a research report on Thursday, May 18th. Argus raised Humana from a “hold” rating to a “buy” rating and set a $260.00 price target on the stock in a research report on Friday, June 9th. Finally, Bank of America Corporation raised their price target on Humana from $270.00 to $275.00 and gave the stock a “buy” rating in a research report on Friday, July 14th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $244.35.

TRADEMARK VIOLATION WARNING: This story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/09/11/zacks-brokerages-anticipate-humana-inc-hum-will-announce-earnings-of-3-23-per-share.html.

In related news, SVP Brian P. Leclaire sold 4,971 shares of the business’s stock in a transaction that occurred on Wednesday, June 28th. The shares were sold at an average price of $240.00, for a total value of $1,193,040.00. Following the completion of the transaction, the senior vice president now directly owns 14,258 shares in the company, valued at approximately $3,421,920. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Elizabeth D. Bierbower sold 9,786 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $259.00, for a total transaction of $2,534,574.00. Following the completion of the transaction, the insider now owns 18,042 shares of the company’s stock, valued at $4,672,878. The disclosure for this sale can be found here. Insiders sold 60,566 shares of company stock worth $15,326,746 over the last three months. 0.80% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Guardian Life Insurance Co. of America grew its position in shares of Humana by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock valued at $119,000 after acquiring an additional 4 shares during the period. Reliance Trust Co. of Delaware boosted its holdings in Humana by 0.7% in the 2nd quarter. Reliance Trust Co. of Delaware now owns 1,123 shares of the insurance provider’s stock worth $270,000 after buying an additional 8 shares during the period. Creative Planning boosted its holdings in Humana by 0.3% in the 2nd quarter. Creative Planning now owns 4,874 shares of the insurance provider’s stock worth $1,173,000 after buying an additional 15 shares during the period. WFG Advisors LP boosted its holdings in Humana by 4.5% in the 2nd quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock worth $113,000 after buying an additional 20 shares during the period. Finally, Cadence Capital Management LLC boosted its holdings in Humana by 0.4% in the 2nd quarter. Cadence Capital Management LLC now owns 5,682 shares of the insurance provider’s stock worth $1,367,000 after buying an additional 22 shares during the period. Institutional investors own 95.14% of the company’s stock.

Humana (NYSE:HUM) traded up 0.25% during mid-day trading on Friday, hitting $257.21. 671,166 shares of the stock were exchanged. The company has a 50-day moving average price of $247.99 and a 200-day moving average price of $230.20. Humana has a one year low of $163.50 and a one year high of $259.76. The company has a market cap of $37.17 billion, a P/E ratio of 21.16 and a beta of 0.87.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Tuesday, August 29th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.62%. Humana’s dividend payout ratio (DPR) is currently 13.06%.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Get a free copy of the Zacks research report on Humana (HUM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Stock Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related stocks with our FREE daily email newsletter.